UROD

Across TCGA pan-cancer cohorts, UROD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UROD data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UROD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UROD expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where UROD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.207	1.000	.002	66	view →
LSCC	DFS	Median	III,IV	0.868	1.000	.027	8	view →
PDAC	DFS	Quartile	III,IV	1.000	0.607	.040	6	view →
UCEC	OS	Median	All	0.918	0.983	.047	2	view →
HNSC	OS	Quartile	III,IV	1.000	0.330	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UROD–LUAD (OS)

Open the LUAD breakdown →